Paper41004573
Targeted inhibition of hepatic de novo ceramide synthesis ameliorates MASH.
Yu X and 23 others. Sci Adv, 2025. Cited by 16 papers, by iCite.
Cite this record
ConductScience Library. Targeted inhibition of hepatic de novo ceramide synthesis ameliorates MASH. Papers, record 41004573. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41004573
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Ceramides | Major topic |
| Liver | Major topic |
| Fatty Liver | Major topic |
| Animals | |
| Humans | |
| Mice | |
| Hepatocytes | |
| Disease Models, Animal | |
| Lipogenesis | |
| Male | |
| RNA, Small Interfering | |
| Serine C-Palmitoyltransferase | |
| Diet, High-Fat | |
| Mice, Inbred C57BL | |
| Nanoparticles |
Source PubMed
References76
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38300524 | Ceramides are fuel gauges on the drive to cardiometabolic disease. | Physiol Rev | 2024 | https://conductscience.org/library/papers/38300524 | PubMed |
| 2 | 34139255 | Therapeutic and diagnostic targeting of fibrosis in metabolic, proliferative and viral disorders. | Adv Drug Deliv Rev | 2021 | https://conductscience.org/library/papers/34139255 | PubMed |
| 3 | 25295789 | CerS2 haploinsufficiency inhibits β-oxidation and confers susceptibility to diet-induced steatohepatitis and insulin resistance. | Cell Metab | 2014 | https://conductscience.org/library/papers/25295789 | PubMed |
| 4 | 31728041 | Multi-technique comparison of atherogenic and MCD NASH models highlights changes in sphingolipid metabolism. | Sci Rep | 2019 | https://conductscience.org/library/papers/31728041 | PubMed |
| 5 | 28038954 | Design of lipid nanoparticles for in vitro and in vivo delivery of plasmid DNA. | Nanomedicine | 2017 | https://conductscience.org/library/papers/28038954 | PubMed |
| 6 | 31805015 | Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. | J Clin Invest | 2020 | https://conductscience.org/library/papers/31805015 | PubMed |
| 7 | 25500885 | Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. | J Clin Invest | 2015 | https://conductscience.org/library/papers/25500885 | PubMed |
| 8 | 40015281 | Hepatic sphingomyelin phosphodiesterase 3 promotes steatohepatitis by disrupting membrane sphingolipid metabolism. | Cell Metab | 2025 | https://conductscience.org/library/papers/40015281 | PubMed |
| 9 | 22707395 | Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. | Hepatology | 2012 | https://conductscience.org/library/papers/22707395 | PubMed |
| 10 | 24827819 | Effect of methionine-deficient and methionine-supplemented diets on the hepatic one-carbon and lipid metabolism in mice. | Mol Nutr Food Res | 2014 | https://conductscience.org/library/papers/24827819 | PubMed |
| 11 | 21286345 | Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease. | Hepatol Int | 2010 | https://conductscience.org/library/papers/21286345 | PubMed |
| 12 | 36753562 | Hepatocytes demarcated by EphB2 contribute to the progression of nonalcoholic steatohepatitis. | Sci Transl Med | 2023 | https://conductscience.org/library/papers/36753562 | PubMed |
| 13 | 33045403 | The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. | Contemp Clin Trials | 2020 | https://conductscience.org/library/papers/33045403 | PubMed |
| 14 | 27125947 | Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. | Eur Heart J | 2016 | https://conductscience.org/library/papers/27125947 | PubMed |
| 15 | 25061561 | Methyl-donor supplementation in obese mice prevents the progression of NAFLD, activates AMPK and decreases acyl-carnitine levels. | Mol Metab | 2014 | https://conductscience.org/library/papers/25061561 | PubMed |
| 16 | 20395294 | Specific contribution of methionine and choline in nutritional nonalcoholic steatohepatitis: impact on mitochondrial S-adenosyl-L-methionine and glutathione. | J Biol Chem | 2010 | https://conductscience.org/library/papers/20395294 | PubMed |
| 17 | 19731235 | Modulation of glycosphingolipid metabolism significantly improves hepatic insulin sensitivity and reverses hepatic steatosis in mice. | Hepatology | 2009 | https://conductscience.org/library/papers/19731235 | PubMed |
| 18 | 29155055 | Cell culture models of fatty acid overload: Problems and solutions. | Biochim Biophys Acta Mol Cell Biol Lipids | 2018 | https://conductscience.org/library/papers/29155055 | PubMed |
| 19 | 33991378 | Assessment of Imaging Modalities Against Liver Biopsy in Nonalcoholic Fatty Liver Disease: The Amsterdam NAFLD-NASH Cohort. | J Magn Reson Imaging | 2021 | https://conductscience.org/library/papers/33991378 | PubMed |
| 20 | 16960033 | Ceramide synthase inhibition by fumonisin B1 treatment activates sphingolipid-metabolizing systems in mouse liver. | Toxicol Sci | 2006 | https://conductscience.org/library/papers/16960033 | PubMed |
Cited by16
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 16 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42989274 | Beyond cholesterol: targeting ceramide signaling in cardiorenal metabolic crosstalk. | Cardiovasc Diabetol | 2026 | https://conductscience.org/library/papers/42989274 | PubMed |
| 42941815 | Sphingolipid Dysregulation in Type 2 Diabetes and Its Microvascular Complications. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42941815 | PubMed |
| 42883860 | Canonical and Non-Canonical Regulators of Lipid Metabolism in the Liver and the "Liver-Other Organs" Axes. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42883860 | PubMed |
| 42866058 | Omics-based Decoding of Metabolic Dysfunction-associated Fatty Liver Disease: From Pathogenesis to Clinical Translation. | J Clin Transl Hepatol | 2026 | https://conductscience.org/library/papers/42866058 | PubMed |
| 42703427 | Nanotherapeutic Strategies for MASLD: From Pathological Mechanisms to Targeted Delivery Systems. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/42703427 | PubMed |
| 42542256 | A targeted lipidomics workflow for high-throughput phenotyping and mechanism-based in vitro hepatotoxicity studies. | Toxicol In Vitro | 2026 | https://conductscience.org/library/papers/42542256 | PubMed |
| 42540234 | Bixin and Montelukast Combination Mitigates the Progression of MASLD to Cytokine-Driven Inflammatory Stress in an In Vitro Fluid-Dynamic Model. | ACS Omega | 2026 | https://conductscience.org/library/papers/42540234 | PubMed |
| 42461367 | Lipidomics and proteomics in MASLD: reading the molecular script toward precision therapeutics. | Hormones (Athens) | 2026 | https://conductscience.org/library/papers/42461367 | PubMed |
| 42346401 | Ceramide-Driven Mechanisms in Pulmonary Fibrosis. | Metabolites | 2026 | https://conductscience.org/library/papers/42346401 | PubMed |
| 42239544 | Sphingolipid homeostasis and dysregulation in liver function and disease. | Life Metab | 2026 | https://conductscience.org/library/papers/42239544 | PubMed |
| 42116125 | Gene therapy for liver diseases: methods, challenges and opportunities. | J Nanobiotechnology | 2026 | https://conductscience.org/library/papers/42116125 | PubMed |
| 42111262 | Research progress on the mechanistic pathways and biomarkers of therapeutic drugs for metabolic-associated steatotic liver disease. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42111262 | PubMed |
| 42021356 | Untargeted plasma lipidomic profiling associated with pediatric metabolic dysfunction-associated steatohepatitis (MASH). | Lipids Health Dis | 2026 | https://conductscience.org/library/papers/42021356 | PubMed |
| 41706239 | MASLD biomarker discovery: evaluating lipidomics techniques across disease progression. | Mol Biol Rep | 2026 | https://conductscience.org/library/papers/41706239 | PubMed |
| 41527118 | Targeted analysis of sphingolipids and cytokines in plasma of dairy cows after calving reveals distinct impacts of systemic inflammation, ketosis, and mastitis. | J Anim Sci Biotechnol | 2026 | https://conductscience.org/library/papers/41527118 | PubMed |
| 41194880 | Anti-obesity effects of Wumeishanzhayin: an integrated lipidomics and transcriptomics study. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/41194880 | PubMed |
Genes13
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41004573
GET https://conductscience.org/api/papers/v1/41004573/authors?page=2